All News

Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.

Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, focus on treatment options for patients with urothelial carcinoma.

The treatment combination elicited partial responses in 80% of patients with squamous NSCLC and 46% in nonsquamous NSCLC.

A recently published study showed that a multicancer early detection blood test was able to identify cancer 3 or more years before a diagnosis.

The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.

SAR446523 is currently being evaluated in a first-in-human phase 1 trial in patients with pretreated relapsed/refractory multiple myeloma.

Researchers have identified the transcription factor CEBPA as a crucial regulator of immune recognition in acute myeloid leukemia.

Researchers have found that donor age is a key determinant of outcomes in hematopoietic cell transplantation, with younger donors associated with significantly better survival and lower rates of GVHD.

Data from the LITESPARK-005 Q-TWiST analysis show belzutifan’s improved quality-adjusted survival time and favorable toxicity profile vs everolimus in RCC.

Management of adverse effects and access to cellular therapies among community oncologists represented key points of discussion in multiple myeloma.

Phase 2 CRDF-004 results revealed that adding onvansertib to chemotherapy/bevacizumab was well tolerated, with no unexpected toxicities observed.

Data from the phase 3 BRUIN CLL-314 trial show a progression-free survival trend favoring pirtobrutinib compared with ibrutinib in patients with CLL/SLL.

“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.

Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.

Priya Jayachandran, MD, FACP, spoke about her new position at El Camino Health as well as her career as a breast oncologist.

The annual Kidney Cancer Research Summit was born from congressional funding for kidney cancer research, according to KidneyCAN president Bryan Lewis.

Results from the phase 3 VIKTORIA-1 trial showed gedatolisib plus fulvestrant with or without palbociclib improved progression-free survival.

AMPLIFY trial results form the basis of the submission, with venetoclax/acalabrutinib showing a PFS advantage vs chemoimmunotherapy in patients with CLL.

Explore innovative strategies and emerging therapies transforming small cell lung cancer treatment, enhancing patient outcomes and survival rates.

Combining renal vaccines with immune therapy may better target tumor cells while limiting harm to healthy tissue, according to David A. Braun, MD, PhD.

Improving data collection and biomarker development across institutions may represent areas of expansion in kidney cancer research.

Following the lifting of a clinical hold, the FDA has again accepted the BLA for tabelecleucel in adult and pediatric patients with EBV-positive PTLD.

KIM-1 is a biomarker in the blood that may help noninvasively detect kidney cancer, according to Wenxin (Vincent) Xu, MD.

Bhuvanesh Singh, MD, has big plans for enhancing the skin cancer program at Northwell Health.

Results from the phase 3 MATTERHORN trial support the FDA’s designations for durvalumab in gastric/gastroesophageal junction cancers.

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

A phase 0 trial is seeking to assess the feasibility of aiding anticancer cells with cytokines to restore their function.

Although pembrolizumab addressed a long-standing need in adjuvant kidney cancer treatment, combinations with the agent may further bolster efficacy.

A proactive regimen reduces dermatologic AEs in patients with NSCLC who were treated with amivantamab and lazertinib, enhancing treatment adherence.